These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8589204)

  • 1. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A.
    Erhardtsen E; Ezban M; Madsen MT; Diness V; Glazer S; Hedner U; Nordfang O
    Blood Coagul Fibrinolysis; 1995 Jul; 6(5):388-94. PubMed ID: 8589204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
    Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE
    Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
    Chowdary P
    Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
    Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE
    Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor.
    van 't Veer C; Hackeng TM; Delahaye C; Sixma JJ; Bouma BN
    Blood; 1994 Aug; 84(4):1132-42. PubMed ID: 8049429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.
    Augustsson C; Svensson A; Kjaer B; Chao TY; Wenjuan X; Krogh BO; Breinholt J; Clausen JT; Hilden I; Petersen HH; Petersen LC
    J Thromb Haemost; 2018 May; 16(5):893-904. PubMed ID: 29532595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma.
    Nordfang O; Valentin S; Beck TC; Hedner U
    Thromb Haemost; 1991 Oct; 66(4):464-7. PubMed ID: 1796397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A ROTEM method using APTT reagent and tissue factor as the clotting activators may better define bleeding heterogeneity in moderate or severe haemophilia A (part I: Study in plasma samples).
    He S; Eelde A; Petrini P; Wallen H; Gabrielsson L; Svensson J; Blombäck M; Holmström M
    Thromb Res; 2018 Nov; 171():7-13. PubMed ID: 30216822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemostatic properties of a TFPI antibody.
    Petersen LC
    Thromb Res; 2012 May; 129 Suppl 2():S44-5. PubMed ID: 22405586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI).
    Dockal M; Hartmann R; Fries M; Thomassen MC; Heinzmann A; Ehrlich H; Rosing J; Osterkamp F; Polakowski T; Reineke U; Griessner A; Brandstetter H; Scheiflinger F
    J Biol Chem; 2014 Jan; 289(3):1732-41. PubMed ID: 24275667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.
    Ogiwara K; Nogami K; Matsumoto T; Shima M
    Int J Hematol; 2014; 99(5):577-87. PubMed ID: 24687919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood.
    Knappe S; Gorczyca ME; Jilma B; Derhaschnig U; Hartmann R; Palige M; Scheiflinger F; Dockal M
    Thromb Haemost; 2013 Mar; 109(3):450-7. PubMed ID: 23348798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas.
    Patel-Hett S; Martin EJ; Mohammed BM; Rakhe S; Sun P; Barrett JC; Nolte ME; Kuhn J; Pittman DD; Murphy JE; Brophy DF
    Haemophilia; 2019 Sep; 25(5):797-806. PubMed ID: 31336410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits.
    Bregengård C; Nordfang O; Wildgoose P; Svendsen O; Hedner U; Diness V
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):699-706. PubMed ID: 8292719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue factor/TFPI and blood cells.
    Osterud B
    Thromb Res; 2012 Mar; 129(3):274-8. PubMed ID: 22197177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting TFPI for hemophilia treatment.
    Peterson JA; Maroney SA; Mast AE
    Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S28-30. PubMed ID: 27207418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue factor pathway.
    McVey JH
    Baillieres Best Pract Res Clin Haematol; 1999 Sep; 12(3):361-72. PubMed ID: 10856975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A.
    Parunov LA; Soshitova NP; Fadeeva OA; Balandina AN; Kopylov KG; Kumskova MA; Gilbert JC; Schaub RG; McGinness KE; Ataullakhanov FI; Panteleev MA
    Thromb Res; 2014 Jan; 133(1):112-9. PubMed ID: 24263002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex.
    Sato Y; Asada Y; Marutsuka K; Hatakeyama K; Kamikubo Y; Sumiyoshi A
    Thromb Haemost; 1997 Sep; 78(3):1138-41. PubMed ID: 9308767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.